Karimpol Polska has signed a lease agreement with biopharmaceutical company Bristol Myers Squibb, which will establish offices in the Skyliner II development in Warsaw. Following the transaction, the office building has reached nearly 70% of its available space leased ahead of completion.
The new office will support Bristol Myers Squibb’s operations in Poland.
“Our Warsaw office will support the company’s mission to discover, develop and deliver innovative medicines. Poland offers a highly skilled and growing talent pool, strong scientific institutions and an environment conducive to advanced research,” said Antoni Żarski, General Manager of Bristol Myers Squibb.
According to Karimpol Polska, the latest agreement reflects continued leasing activity at the project before construction has been completed.
“The lease signed with Bristol Myers Squibb represents another stage in the commercialisation of Skyliner II. The continued interest from international occupiers demonstrates demand for well-located, high-quality office space,” said Karimpol Polska.
Skyliner II is the second phase of the Karimpol Group’s office development at Rondo Daszyńskiego in Warsaw. Construction is progressing according to schedule, with completion planned by the end of 2026.
The building will provide more than 24,000 sqm of leasable space, including over 23,000 sqm of office accommodation and almost 1,100 sqm of retail and service space on the ground floor.
The development will include a five-level underground car park with 217 parking spaces, parking for 100 bicycles and four landscaped terrace levels designed by RS Landscape Architecture. The project was designed by APA Wojciechowski Architekci, with WARBUD serving as general contractor and Hill International providing project management and investor supervision.
Skyliner II is targeting high environmental performance standards. The building has been awarded BREEAM New Construction Outstanding certification and is planned to operate using electricity sourced entirely from renewable energy.